Trillium Therapeutics Inc (TRIL)

[NY1972]

Tumoral IFN? mRNA and PD-L1 protein expression to overall survival(NSCLC)

# Pts (# events) Median in months (95% CI) Adjusted HRa; p
IFN?+/PD-L1+ 43 (11) NR (8.8, NA) 0.40; 0.016
IFN?+/PD-L1? 20 (8) NR (6.5, NA) 0.38; 0.021
IFN??/PD-L1+ 42 (16) 9.7 (5.1, NA) 0.64; 0.18
IFN??/PD-L1? 52 (34) 5.9 (4.1, 10.2)
NR=Not Reached; NA=Not Applicable; a Univariate log-rank p<0.05 for all adjusted p <0.05 (not shown)

http://abstracts.asco.org/176/AbstView_176_169691.html